Side-by-side · Research reference

CartalaxvsMelanotan-II

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED10/32 cited

BPhase 1HUMAN-REVIEWED9/43 cited

Cartalax

Bioregulator Peptide · Khavinson School

CartilagePrimary tissuePovorozniuk 2007

MSC → ChondrocyteDifferentiation axisLinkova 2023

BMD ↑Bone density effectPovorozniuk 2007

SQ · Protocol Unspecified

Melanotan-II

MC1R + MC4R agonist · Tanning + sexual response

0.25–1.0 mgPer doseDorr 1996

Phase 1Evidence levelDorr 1996

~1 hrHalf-life

SQ · Abdomen · Loading 5–7 days, then maintenance

01Mechanism of Action

Parameter

Cartalax

Melanotan-II

Primary target

Mesenchymal stem cells (MSCs) undergoing chondrogenic differentiationLinkova 2023

MC1R (skin) + MC3R + MC4R (CNS sexual / appetite)Dorr 1996

Pathway

Modulation of WNT, ERK-p38, and Smad 1/5/8 signaling pathwaysLinkova 2023

MC1R agonism → melanocyte tyrosinase → eumelanin synthesis. MC4R → autonomic sexual arousal centresDorr 1996 Simerly 2023

Downstream effect

Upregulation of chondrogenic genes (COL2, SOX9, ACAN); increased bone mineral density; osteoprotective effects in ovariectomy-induced osteoporosisLinkova 2023 Povorozniuk 2007

Skin darkening, photo-protection, increased sexual desire / spontaneous erectionDorr 1996

Feedback intact?

—

Origin

Derived from cartilaginous tissue extracts (Khavinson bioregulator methodology)Povorozniuk 2007

Cyclic 7-AA modified α-MSH analog; designed at University of ArizonaDorr 1996

Antibody development

—

02Dosage Protocols

Parameter

Cartalax

Melanotan-II

Animal model dose

Unspecified (cartilaginous tissue extract protocol)

Rat study; extract preparation details not indexed in available abstracts.

—

Human dosing

Not established in PubMed-indexed literature

Russian-tradition protocols exist but lack peer-reviewed Western validation.

—

Evidence basis

Animal mechanistic studies only

Phase 1 + anecdotalDorr 1996

Loading phase

—

0.25–0.5 mg/day SQ × 5–7 daysDorr 1996

Builds up to visible tan.

Maintenance

—

0.5–1.0 mg 1–2×/week

After visible tan develops; supports with UV exposure.

Frequency

—

Daily during loading; 1–2× per week maintenance

Lower / starter dose

—

0.1 mg / day

Conservative starter — assess tolerability for nausea.

Duration

—

8–12 weeks per cycle

Reconstitution

—

Bacteriostatic water; protect from light

Timing

—

Evening preferred (24h tan-development cycle)

Half-life

—

~1 hour plasma; effects on melanocytes persist days

03Metabolic / Fat Loss Evidence

Parameter

Cartalax

Melanotan-II

Fat loss evidence

None — primary target is cartilage and bone tissue, not adipose

—

04Side Effects & Safety

Parameter

Cartalax

Melanotan-II

Documented adverse effects

None reported in indexed animal studies

—

Human safety data

Not available in PubMed-indexed literature

—

Nausea

—

Common, especially loading phase

Flushing

—

Common transient

Spontaneous erection

—

Common in men — MC4R cross-effectDorr 1996

Increased mole / freckle pigmentation

—

Existing moles darken; new lesions possible

Melanoma risk

—

Theoretical concern — increased melanocyte activity; CAUTION in melanoma history

Appetite suppression

—

MC4R-mediated; mild

Pregnancy / OB

—

Contraindicated

Absolute Contraindications

Cartalax

·Unknown due to lack of human clinical trial data

Melanotan-II

·History of melanoma or atypical mole syndrome
·Pregnancy / breastfeeding
·Active uncontrolled hypertension

Relative Contraindications

Cartalax

·Active malignancy (theoretical; peptide bioregulators may influence cell proliferation pathways)

Melanotan-II

·Significant freckling / dysplastic nevus
·Personal or family melanoma history

05Administration Protocol

Parameter

Cartalax

Melanotan-II

1. Route

Subcutaneous injection typical for Khavinson bioregulators; specific protocols not detailed in indexed literature.

Add 2 mL bacteriostatic water to 10 mg vial → 5 mg/mL = 500 mcg per 0.1 mL. Light-protected.

2. Frequency

Russian-tradition protocols often employ 10-day cycles; precise frequency unspecified in available abstracts.

SQ — abdomen. Rotate sites.

3. Storage

Lyophilised peptide bioregulators typically stored at 2–8 °C, light-protected. Reconstitution details not indexed.

Evening preferred. UV exposure (sunlight or tanning bed) helps develop tan.

4. Storage

—

Lyophilised: refrigerate, light-protected. Reconstituted: refrigerate ≤30 days.

5. Needle

—

29–31G insulin syringe.